Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Agios Pharmaceuticals Inc. maintains a portfolio within the Biotechnology & Pharmaceuticals technology area, currently featuring 4 pending office actions. These actions are distributed across 4 distinct examiners, which provides a variety of individual reviews for the company's applications. Prosecution activity is spread across 2 distinct art units, showing that the technology touches upon multiple examination groups within the patent office. This distribution suggests a diverse approach to the company's pharmaceutical innovations.
KIFLE, BRUCK is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending action. This examiner's workload represents a portion of the 4 total pending actions, as the 4 distinct examiners each handle a share of the portfolio. The presence of 2 distinct art units alongside 4 distinct examiners indicates that multiple examiners are working within the same art unit or across the 2 identified areas. Practitioners can observe that the busiest examiner pending count is limited to 1, which reflects the current distribution of the workload across the examination staff.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| PIHONAK, SARAH | 1 | 61.3% | +42.6% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028058 | PHARMACEUTICAL FORMULATION | LEE, SIN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288888 | METHODS FOR TITRATING MITAPIVAT | RZECZYCKI, PHILLIP MATTHEW | 22d |
| 18882884 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | KIFLE, BRUCK | — |
| 18841478 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PIHONAK, SARAH | — |
| 18028058 | PHARMACEUTICAL FORMULATION | LEE, SIN J | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18882884 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | KIFLE, BRUCK | — | DP | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18841478 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PIHONAK, SARAH | — | §102 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18288888 | METHODS FOR TITRATING MITAPIVAT | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103 | Final Rejection | 22d | Pending | Oct 30, 2023 |
| 18028058 | PHARMACEUTICAL FORMULATION | LEE, SIN J | 1613 | §103§112 | Non-Final OA | — | Pending | Mar 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial